Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy. Basic parameters: from 19 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Algeria
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Detailed description
This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients.
Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.
Primary outcome measures
- Socio-demographic characteristics of patients with prostate cancer in Algeria [Time frame: At Baseline ( Initial visit )]
- Personal and family history of cancer [Time frame: At Baseline (Initial Visit)]
- Environmental and occupational exposures [Time frame: At Baseline (Initial visit)]
- Smoking history [Time frame: At Baseline (Initial visit)]
- Alcohol consumption [Time frame: At Baseline (Initial visit)]
- Initial symptoms and circumstances of diagnosis [Time frame: At Baseline (Initial visit)]
- International Prostate Symptom Score (IPSS) [Time frame: At Baseline (Initial visit)]
- Evolutionary status of patients [Time frame: At Baseline (Initial visit)]
Secondary outcome measures (12)
- Diagnosis by PSA testing [Time frame: At Baseline (Initial visit)]
- Diagnosis by imaging [Time frame: At Baseline (Initial visit)]
- Diagnosis by biopsy [Time frame: At Baseline (Initial visit)]
- Time from symptom onset to first medical consultation [Time frame: At Baseline (Initial visit)]
- Time from first consultation to confirmed diagnosis [Time frame: At Baseline (Initial visit)]
- Patients discussed in multidisciplinary team meetings [Time frame: At Baseline (Initial visit)]
- Initial treatment: Surgery [Time frame: At Baseline (Initial visit)]
- Initial treatment: Radiotherapy [Time frame: At Baseline (Initial visit)]
- Initial treatment: Hormone therapy [Time frame: At Baseline (Initial visit)]
- Initial treatment: Active surveillance [Time frame: At Baseline (Initial visit)]
- Time from diagnosis to treatment initiation [Time frame: At Baseline (Initial visit)]
- Specialty of physician initiating treatment [Time frame: At Baseline (Initial visit)]
Eligibility criteria
Inclusion criteria
- Patients aged 19 years and older.
- Diagnosis of prostate cancer confirmed histologically and/or biologically.
- Patients followed in the participating oncology departments.
- Written informed consent obtained.
Non Inclusion Criteria:
- Histological types other than carcinoma
- Secondary tumors
- Participation in an interventional study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
Algeria · 24 centers
- CAC Adrar - Oncology Department — Adrar
- CAC Adrar - Radiotherapy Department — Adrar
- CAC BLIDA - Oncology Department — Algiers
- Centre Pierre et Marie Curie - Oncology Department — Algiers
- Centre Pierre et Marie Curie - Radiology Department — Algiers
- CHU Bab El Oued — Algiers
- CHU Béni Messous - Oncology Departement — Algiers
- EPH ROUIBA - Oncology Department — Algiers
- … and 16 more centers
Identifiers
NCT: NCT07484971 · SAFRO 02.002